MBOT - Microbot stock rises after plans of trial of LIBERTY robotic system in Brazil moves ahead
2023-05-08 09:28:35 ET
- Microbot Medical ( NASDAQ: MBOT ) said it started preparations for potential first-in-human (FIH) cases in Brazil for its LIBERTY robotic system.
- The engaging of Francisco Cesar Carnevale from the University of Sao Paulo Medical School Hospital, is expected to support Microbot's plan to conduct a FIH clinical trial in Brazil as part of its ongoing clinical and regulatory efforts.
- "Following the successful usage of the LIBERTY system in over 100 pre-clinical catheterization procedures, and the value the Key Opinion Leaders that have performed those cases see in the LIBERTY system, the engagement with Prof. Carnevale to perform the first clinical cases represents a major step as we aim to continue our efforts toward regulatory approvals and commercialization," said Chairman, President and CEO Harel Gadot.
- The potential cases are expected to start after verification and validation process of the LIBERTY system, and getting regulatory approvals for the cases, the company added.
- The company believes that LIBERTY's remote operation has the potential to be the first system to democratize endovascular interventional procedures.
- MBOT +9.01% to $1.21 premarket May 8
For further details see:
Microbot stock rises after plans of trial of LIBERTY robotic system in Brazil moves ahead